ClinicalTrials.gov record
Completed Phase 2 Interventional

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

ClinicalTrials.gov ID: NCT01300208

Public ClinicalTrials.gov record NCT01300208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Study identification

NCT ID
NCT01300208
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
48 participants

Conditions and interventions

Interventions

  • CC-11050 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2010
Primary completion
Dec 31, 2012
Completion
Feb 28, 2013
Last update posted
Jun 22, 2020

2010 – 2013

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Northwest Arkansas Clinical Trials Center, PLLC Rogers Arkansas 72758
Dermatology Research Associates Los Angeles California 90045
Medderm Associates San Diego California 92103
Emory Univ. School of Medicine Atlanta Georgia 30322
Peachtree Dermatology Associates Research Center Atlanta Georgia 30327
Central Medaphase Inc Newnan Georgia 30263
Northwestern University Chicago Illinois 60611
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46256
DermResearch, PLLC Louisville Kentucky 40217
Dermatology & Advanced Aesthetics Lake Charles Louisiana 70605
Central Dermatology, P.C. St Louis Missouri 63117
NYU Langone Medical Center New York New York 10016
University Hospitals Case Medical Center Cleveland Ohio 44106
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
Penn State Hershey Dermatology Hershey Pennsylvania 17033
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Clinical Partners, LLC Johnston Rhode Island 02919
UT Southwestern Medical Center Dallas Dallas Texas 75390-9090

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01300208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2020 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01300208 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →